Janine Erler became interim CEO of NEUmiRNA Therapeutics (a biotech firm focused on transformative disease modification specifically for neurological conditions) in 2022.
Janine Erler has a 22-year+ career in cancer research and has retained her fully-tenured Professor position at the University of Copenhagen while also heading up a commercial biotech research firm. Here’s her comment on what it takes to combine both academia and business.
Leave a Reply